{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Liquidia Corporation"},"Symbol":{"label":"Symbol","value":"LQDA"},"Address":{"label":"Address","value":"419 DAVIS DRIVE,SUITE 100, MORRISVILLE, North Carolina, 27560, United States"},"Phone":{"label":"Phone","value":"+1 919 328-4400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension."},"CompanyUrl":{"label":"Company Url","value":"https://www.liquidia.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Kaseta","title":"Chief Financial & Operating Officer"},{"name":"Rajeev Saggar","title":"Chief Medical Officer"},{"name":"Roger A. Jeffs","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}